Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies.

Scott Alexander proposes using high-dose oral progesterone as a potential low-cost alternative to Zulresso for treating postpartum depression, based on pharmacological research.

Scott Alexander compiles reader comments on healthcare systems in various countries, discussing economics, drug pricing, and personal experiences.

Scott Alexander reviews comments on his posts about aducanumab and the FDA, acknowledging some mistakes while defending his overall critique of FDA conservatism.

Scott Alexander argues that the FDA is too strict, not too lax, and proposes unbundling FDA approval to allow for more nuanced drug regulation.

Scott Alexander provides a comprehensive guide on ketamine as a depression treatment, covering administration methods, effectiveness, safety, dosage, and potential side effects.

Scott Alexander criticizes the emergence of expensive, prescription-only therapy apps, using Somryst (a CBT-i app) as an example, and warns about the normalization of this trend.

Scott Alexander examines the Amish health care system, which costs much less than the American system while maintaining good health outcomes, and considers its implications for broader healthcare policy.

Scott Alexander follows up on his critique of a book about the Baumol effect, presenting data that challenges the book's claims about rising wages driving cost increases in education and healthcare.

Scott Alexander reviews a book attributing rising service costs to the Baumol effect, finding it convincing but raising some concerns about conflicting data and affordability issues.

Scott Alexander proposes a hypothetical low-cost psychiatric practice to combat medical cost disease, exploring its potential and the barriers to its implementation.

Scott Alexander offers various strategies for obtaining affordable mental health care and medication in the US, including discount programs, therapy alternatives, and supplement options.

A collection of links covering topics from drug regulation and genetic testing to tax reform and AI developments, with Scott's commentary on each item.

Scott Alexander summarizes various responses to his post on 'cost disease', presenting diverse explanations for dramatic cost increases in healthcare, education, and infrastructure.

Scott Alexander examines the phenomenon of cost disease, where costs for basic services like education and healthcare have increased dramatically without corresponding improvements in quality or wages.

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox.

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies.

A collection of interesting links covering research studies, social issues, economic trends and cultural phenomena that challenged expectations.

Scott Alexander critiques the inefficiency of psychiatric care for poverty-related issues, suggesting a Basic Income Guarantee as a potentially more effective solution.

Scott Alexander examines overpriced medical products like Lovaza and Deplin, arguing they serve a purpose in the medical system, but criticizes exorbitant BRCA gene testing prices as harmful.

A collection of interesting links covering history, science, economics, and culture, with Scott's commentary and observations on each topic.

Scott Alexander critiques the medical system's preference for expensive prescription sleep aids like Ramelteon over cheaper alternatives like melatonin, while sharing interesting facts about melatonin's uses.